Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).
Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.
The European Commission has approved cemiplimab-rwlc plus platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without EGFR, ALK, or ROS1 alterations and who are not eligible for chemoradiation.